Inscription Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.13M | Buy |
20,373
+2,505
| +14% | +$539K | 0.45% | 37 |
|
|
2026
Q1 | $3.89M | Sell |
17,868
-1,459
| -8% | -$324K | 0.41% | 39 |
|
|
2025
Q4 | $4.42M | Buy |
19,327
+1,427
| +8% | +$325K | 0.45% | 37 |
|
|
2025
Q3 | $4.14M | Buy |
17,900
+666
| +4% | +$136K | 0.45% | 39 |
|
|
2025
Q2 | $3.2M | Sell |
17,234
-1,946
| -10% | -$362K | 0.46% | 39 |
|
|
2025
Q1 | $3.49M | Buy |
+19,180
| New | +$3.73M | 0.58% | 33 |
|
|
2024
Q3 | $3.71M | Sell |
18,786
-158
| -0.8% | -$29.5K | 0.55% | 34 |
|
|
2024
Q2 | $3.25M | Sell |
18,944
-236
| -1% | -$39.1K | 0.52% | 36 |
|
|
2024
Q1 | $3.49M | Buy |
19,180
+3,263
| +21% | +$562K | 0.58% | 33 |
|
|
2023
Q4 | $2.47M | Buy |
15,917
+451
| +3% | +$65.8K | 0.67% | 32 |
|
|
2023
Q3 | $2.31M | Buy |
15,466
+424
| +3% | +$62.2K | 0.75% | 28 |
|
|
2023
Q2 | $2.03M | Sell |
15,042
-359
| -2% | -$52.6K | 0.63% | 33 |
|
|
2023
Q1 | $2.45M | Buy |
15,401
+662
| +4% | +$101K | 0.65% | 34 |
|
|
2022
Q4 | $2.38M | Sell |
14,739
-83
| -0.6% | -$12.7K | 0.82% | 29 |
|
|
2022
Q3 | $1.99M | Sell |
14,822
-14,846
| -50% | -$2.13M | 0.56% | 34 |
|
|
2022
Q2 | $4.54M | Buy |
29,668
+13,831
| +87% | +$2.11M | 0.82% | 26 |
|
|
2022
Q1 | $2.57M | Sell |
15,837
-257
| -2% | -$37.3K | 0.73% | 32 |
|
|
2021
Q4 | $2.18M | Buy |
16,094
+1,720
| +12% | +$203K | 0.6% | 45 |
|
|
2021
Q3 | $1.55M | Sell |
14,374
-23,372
| -62% | -$2.67M | 0.49% | 55 |
|
|
2021
Q2 | $4.25M | Buy |
37,746
+22,771
| +152% | +$2.56M | 0.48% | 46 |
|
|
2021
Q1 | $1.62M | Sell |
14,975
-762
| -5% | -$81.5K | 0.55% | 51 |
|
|
2020
Q4 | $1.69M | Sell |
15,737
-485
| -3% | -$46.6K | 0.65% | 47 |
|
|
2020
Q3 | $1.42M | Buy |
16,222
+55
| +0.3% | +$5.18K | 0.63% | 48 |
|
|
2020
Q2 | $1.59M | Sell |
16,167
-411
| -2% | -$36.2K | 0.88% | 33 |
|
|
2020
Q1 | $1.26M | Sell |
16,578
-293
| -2% | -$25K | 0.84% | 34 |
|
|
2019
Q4 | $1.49M | Buy |
16,871
+2,270
| +16% | +$188K | 0.66% | 42 |
|
|
2019
Q3 | $1.11M | Buy |
+14,601
| New | +$1M | 0.61% | 50 |
|
|
2019
Q2 | – | Sell |
-801
| Closed | -$65K | – | 107 |
|
|
2019
Q1 | $65K | Sell |
801
-256
| -24% | -$20.9K | 0.03% | 179 |
|
|
2018
Q4 | $97K | Buy |
+1,057
| New | +$93K | 0.05% | 161 |
|
Other funds holding ABBV
Inscription Capital's ABBV Position: Q2 2026 in Review
Inscription Capital increased its AbbVie (ABBV) stake by 14% in Q2 2026, buying an estimated $539K and bringing the position to 20,373 shares worth $5.13M. The position accounts for 0.45% of the portfolio, ranked #37.
Inscription Capital first reported a position in ABBV in Q4 2018 and has held it in 29 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Inscription Capital held 20,373 shares of AbbVie worth $5.13M as of Q2 2026.
- Inscription Capital bought 2,505 AbbVie shares in Q2 2026, an estimated $539K.
- AbbVie made up 0.45% of Inscription Capital's portfolio in Q2 2026, its #37 holding.
- Inscription Capital first reported a position in AbbVie in Q4 2018 and has held it in 29 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.